388 related articles for article (PubMed ID: 30867590)
1. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Rueda OM; Sammut SJ; Seoane JA; Chin SF; Caswell-Jin JL; Callari M; Batra R; Pereira B; Bruna A; Ali HR; Provenzano E; Liu B; Parisien M; Gillett C; McKinney S; Green AR; Murphy L; Purushotham A; Ellis IO; Pharoah PD; Rueda C; Aparicio S; Caldas C; Curtis C
Nature; 2019 Mar; 567(7748):399-404. PubMed ID: 30867590
[TBL] [Abstract][Full Text] [Related]
2. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
4. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
[TBL] [Abstract][Full Text] [Related]
6. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
7. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
8. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Allison KH
Mod Pathol; 2021 Jan; 34(Suppl 1):94-106. PubMed ID: 33154551
[TBL] [Abstract][Full Text] [Related]
11. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
12. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Metzger-Filho O; Sun Z; Viale G; Price KN; Crivellari D; Snyder RD; Gelber RD; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Cardoso F
J Clin Oncol; 2013 Sep; 31(25):3083-90. PubMed ID: 23897954
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW
Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592
[TBL] [Abstract][Full Text] [Related]
15. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
[TBL] [Abstract][Full Text] [Related]
16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
17. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
Ogiya A; Yamazaki K; Horii R; Shien T; Horimoto Y; Masuda N; Inao T; Hosoda M; Ishida N; Osako T; Takahashi M; Endo Y; Miyoshi Y; Yasojima H; Tomioka N; Yamashita H;
Breast Cancer; 2017 May; 24(3):473-482. PubMed ID: 27628678
[TBL] [Abstract][Full Text] [Related]
18. Triple negative breast cancer: from molecular portrait to therapeutic intervention.
Carotenuto P; Roma C; Rachiglio AM; Botti G; D'Alessio A; Normanno N
Crit Rev Eukaryot Gene Expr; 2010; 20(1):17-34. PubMed ID: 20528735
[TBL] [Abstract][Full Text] [Related]
19. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
20. Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.
Minicozzi P; Bella F; Toss A; Giacomin A; Fusco M; Zarcone M; Tumino R; Falcini F; Cesaraccio R; Candela G; La Rosa F; Federico M; Sant M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1569-77. PubMed ID: 23892409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]